The antibacterial medicine sales in Sweden, expressed in US Dollars PPP per capita, show a steady increment from 2024 to 2028. The values forecasted reveal a consistent growth from 8.3 in 2024 to 8.6 in 2028. Year-on-year percentage variations show a small but steady increase: the growth rate is 1.2% from 2024 to 2025, 1.2% from 2025 to 2026, 0% from 2026 to 2027, and 1.2% from 2027 to 2028. This indicates a stable demand for antibacterial medicines in the Swedish market.
In 2023, the actual per capita value was 8.2, marking a baseline for the subsequent forecasted growth. Over the past two years, the annual compound growth rate (CAGR) has averaged 0.96%. This pattern displays optimism but signals a plateau in growth from 2026 to 2027. Key factors contributing to this stability include advancements in healthcare, stringent regulatory policies concerning antibiotic use, and public awareness campaigns regarding antibiotic resistance.
Looking forward, trends to watch for include technological advancements in antibacterial treatment, changes in regulatory policies, and public health initiatives aimed at reducing antibiotic resistance. Monitoring these trends will be crucial to understanding future market dynamics and potential disruptions.
